127 related articles for article (PubMed ID: 10684748)
1. A randomized controlled trial of a clinic-based support staff intervention to increase the rate of fecal occult blood test ordering.
Thompson NJ; Boyko EJ; Dominitz JA; Belcher DW; Chesebro BB; Stephens LM; Chapko MK
Prev Med; 2000 Mar; 30(3):244-51. PubMed ID: 10684748
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
[TBL] [Abstract][Full Text] [Related]
3. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
Sharma VK; Corder FA; Fancher J; Howden CW
Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
[TBL] [Abstract][Full Text] [Related]
4. Does use of the Coloscreen Self-Test improve patient compliance with fecal occult blood screening?
Park SI; Saxe JC; Weesner RE
Am J Gastroenterol; 1993 Sep; 88(9):1391-4. PubMed ID: 8362837
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.
Stokamer CL; Tenner CT; Chaudhuri J; Vazquez E; Bini EJ
J Gen Intern Med; 2005 Mar; 20(3):278-82. PubMed ID: 15836533
[TBL] [Abstract][Full Text] [Related]
6. Screening for colorectal cancer.
Mandel JS
Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
[TBL] [Abstract][Full Text] [Related]
7. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
[TBL] [Abstract][Full Text] [Related]
9. Fecal occult blood test performance indicators in warfarin-treated patients.
Kershenbaum A; Lavi I; Rennert G; Almog R
Dis Colon Rectum; 2010 Feb; 53(2):224-9. PubMed ID: 20087099
[TBL] [Abstract][Full Text] [Related]
10. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW
Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
[TBL] [Abstract][Full Text] [Related]
11. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
12. [Fecal occult blood test and mass screening for colorectal cancer].
Saito H; Soma Y; Kawaguchi H
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2232-40. PubMed ID: 1929443
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics of colorectal carcinomas detected by mass screening].
Kikkawa N; Tsuchiya Y; Matsui S; Murai M; Yamamoto H; Matsui K
Gan No Rinsho; 1989 Jul; 35(8):923-6. PubMed ID: 2746866
[TBL] [Abstract][Full Text] [Related]
14. Improving colorectal cancer screening in a medical residents' primary care clinic.
Struewing JP; Pape DM; Snow DA
Am J Prev Med; 1991; 7(2):75-81. PubMed ID: 1910891
[TBL] [Abstract][Full Text] [Related]
15. The role of family physicians in increasing annual fecal occult blood test screening coverage: a prospective intervention study.
Vinker S; Nakar S; Rosenberg E; Kitai E
Isr Med Assoc J; 2002 Jun; 4(6):424-5. PubMed ID: 12073414
[TBL] [Abstract][Full Text] [Related]
16. Population colorectal cancer screening with fecal occult blood test.
Rennert G; Rennert HS; Miron E; Peterburg Y
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
[TBL] [Abstract][Full Text] [Related]
17. Mailings timed to patients' appointments: a controlled trial of fecal occult blood test cards.
Goldberg D; Schiff GD; McNutt R; Furumoto-Dawson A; Hammerman M; Hoffman A
Am J Prev Med; 2004 Jun; 26(5):431-5. PubMed ID: 15165660
[TBL] [Abstract][Full Text] [Related]
18. A provider intervention to improve colorectal cancer screening in county health centers.
Lane DS; Messina CR; Cavanagh MF; Chen JJ
Med Care; 2008 Sep; 46(9 Suppl 1):S109-16. PubMed ID: 18725822
[TBL] [Abstract][Full Text] [Related]
19. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening.
Myers RE; Sifri R; Hyslop T; Rosenthal M; Vernon SW; Cocroft J; Wolf T; Andrel J; Wender R
Cancer; 2007 Nov; 110(9):2083-91. PubMed ID: 17893869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
